We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 23, 2011

[90Y-DOTA]-TOC May Improve Survival in Metastatic Neuroendocrine Tumors

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Response, Survival, and Long-Term Toxicity After Therapy With the Radiolabeled Somatostatin Analogue [90Y-DOTA]-TOC in Metastasized Neuroendocrine Cancers
J. Clin. Oncol 2011 May 09;[EPub Ahead of Print], A Imhof, P Brunner, N Marincek, M Briel, C Schindler, H Rasch, HR Mäcke, C Rochlitz, J Müller-Brand, MA Walter

Further Reading